花旗:友邦(1299.HK)新CEO上场 料业务重点转向中国扩张
中国平安(02318.HK)首席执行官李源祥将出任友邦(01299.HK)首席执行官兼总裁,以代替明年5月底退休的黄经辉。花旗发表报告指,相信此举将为友邦业务开启新一页,将集中扩张中国市场,相信李源祥可更好地与中国各省份之监管当局沟通,及招聘当地经纪,以开启更多业务地区。
该行亦相信李源祥接任後可令友邦中分销渠道更多元化,及提升其科技含量。另外,解决继任人问题对股价造成的不确定因素亦消除,相信除了香港政治事件将令股价短期受压外,其中国业务发展可长期推动股价表现。该行给予友邦目标价90港元,评级“买入”。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.